Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 2 | 3 |
| 1998 | 3 | 6 | 9 |
| 1999 | 1 | 2 | 3 |
| 2000 | 3 | 1 | 4 |
| 2001 | 1 | 4 | 5 |
| 2002 | 4 | 1 | 5 |
| 2003 | 3 | 2 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 4 | 7 | 11 |
| 2006 | 2 | 9 | 11 |
| 2007 | 3 | 6 | 9 |
| 2008 | 4 | 5 | 9 |
| 2009 | 4 | 2 | 6 |
| 2010 | 4 | 4 | 8 |
| 2011 | 10 | 3 | 13 |
| 2012 | 4 | 3 | 7 |
| 2013 | 3 | 10 | 13 |
| 2014 | 5 | 8 | 13 |
| 2015 | 2 | 8 | 10 |
| 2016 | 9 | 7 | 16 |
| 2017 | 3 | 10 | 13 |
| 2018 | 5 | 5 | 10 |
| 2019 | 9 | 8 | 17 |
| 2020 | 10 | 4 | 14 |
| 2021 | 3 | 4 | 7 |
| 2022 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Upregulation of the EGFR/MEK1/MAPK1/2 signaling axis as a mechanism of resistance to antiestrogen-induced BimEL dependent apoptosis in ER+ breast cancer cells. Int J Oncol. 2023 Feb; 62(2).
-
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in?vitro and in?vivo. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2201073119.
-
miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer. Int J Mol Sci. 2022 Jul 22; 23(15).
-
A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells. BMC Pulm Med. 2022 Jan 07; 22(1):27.
-
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.
-
Dependence of ABCB1 transporter expression and function on distinct sphingolipids generated by ceramide synthases-2 and -6 in chemoresistant renal cancer. J Biol Chem. 2022 02; 298(2):101492.
-
Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol. 2021 10 06; 22(11):105.
-
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Res. 2021 12 01; 81(23):5818-5832.
-
Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021 May 24; 22(11).
-
FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells. Int J Mol Sci. 2021 Jan 13; 22(2).